bluebird bio, Inc. (NASDAQ:BLUE) insider Jason Cole sold 1,129 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $173.38, for a total transaction of $195,746.02. Following the sale, the insider now directly owns 19,945 shares of the company’s stock, valued at $3,458,064.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at $169.50 on Wednesday. The stock has a market cap of $7,770.00, a PE ratio of -24.18 and a beta of 2.08. bluebird bio, Inc. has a 12 month low of $63.10 and a 12 month high of $222.03.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. bluebird bio’s revenue was up 397.4% compared to the same quarter last year. During the same quarter last year, the company earned ($2.07) EPS. research analysts forecast that bluebird bio, Inc. will post -6.72 earnings per share for the current year.

A number of analysts recently weighed in on BLUE shares. Wedbush reaffirmed an “outperform” rating and set a $174.00 price target (up from $135.00) on shares of bluebird bio in a research report on Thursday, November 2nd. Cantor Fitzgerald reaffirmed a “sell” rating and set a $39.00 price target on shares of bluebird bio in a research report on Thursday, September 28th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target for the company in a research report on Monday, October 16th. BMO Capital Markets upped their price target on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 price target on shares of bluebird bio in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company. bluebird bio presently has an average rating of “Hold” and a consensus price target of $157.45.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLUE. FMR LLC raised its stake in bluebird bio by 9.6% during the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares during the period. Capital Research Global Investors raised its stake in bluebird bio by 9.9% during the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after acquiring an additional 493,072 shares during the period. Vanguard Group Inc. raised its stake in bluebird bio by 10.7% during the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after acquiring an additional 343,856 shares during the period. Eagle Asset Management Inc. acquired a new stake in bluebird bio during the third quarter worth about $29,539,000. Finally, American Century Companies Inc. acquired a new stake in bluebird bio during the third quarter worth about $31,170,000.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/insider-selling-bluebird-bio-inc-blue-insider-sells-1129-shares-of-stock/1801017.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.